Kopran vs Syncom Formulations vs Shree Ganesh Remedies: Which Stock Should You Track
- October 13, 2026
- Posted by: Chaitanya Auti
- Category: Market
Kopran PE 49.10, mkt cap Rs 1,227 crore. Syncom Formulations (India) PE 25.91, mkt cap Rs 2,217 crore. Shree Ganesh Remedies PE 58.77, mkt cap Rs 907 crore.
Quick Answer
Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies is a side-by-side comparison of three companies from the pharma and biotech space. On this comparison, Kopran carries a market capitalisation of about Rs 1,227 crore, against Rs 2,217 crore for Syncom Formulations (India) and Rs 907 crore for Shree Ganesh Remedies, with return on equity of 4.85%, 18.42% and 10.90% respectively. Each company’s numbers are presented here without a declared preference, since the right stock depends on an investor’s own criteria.
Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies starts with the core numbers most investors compare within the pharma and biotech segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the pharma and biotech bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.
Click Here – Get Free Investment Predictions
Kopran, Syncom Formulations (India) and Shree Ganesh Remedies: Company Overview
Kopran is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,227 crore, a return on equity of 4.85% and a book value of Rs 109.74 per share. Its quarterly revenue moved from Rs 137.78 crore in June 2025 to Rs 156.04 crore in June 2026, a change of +13.3%.
Syncom Formulations (India) is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,217 crore, a return on equity of 18.42% and a book value of Rs 4.41 per share. Its quarterly revenue moved from Rs 122.93 crore in June 2025 to Rs 133.36 crore in June 2026, a change of +8.5%.
Shree Ganesh Remedies is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 907 crore, a return on equity of 10.90% and a book value of Rs 126.95 per share. Its quarterly revenue moved from Rs 25.33 crore in June 2025 to Rs 15.30 crore in June 2026, a change of -39.6%.
Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Valuation and Profitability Snapshot
| Metric | Kopran | Syncom Formulations (India) | Shree Ganesh Remedies |
|---|---|---|---|
| Market Cap (approx.) | Rs 1,227 crore | Rs 2,217 crore | Rs 907 crore |
| PE Ratio (TTM) | 49.10 | 25.91 | 58.77 |
| PB Ratio | 2.31 | 5.34 | 5.56 |
| Return on Equity (ROE) | 4.85% | 18.42% | 10.90% |
| EPS (TTM, Rs) | 5.17 | 0.91 | 12.02 |
| Dividend Yield | 1.18% | 0.42% | 0.00% |
| Debt to Equity | 0.29 | 0.00 | 0.19 |
| Book Value per Share (Rs) | 109.74 | 4.41 | 126.95 |
Check the Univest Screener for Live Data
On valuation, Kopran trades at a PE of 49.10 and a PB of 2.31, Syncom Formulations (India) at a PE of 25.91 and a PB of 5.34, while Shree Ganesh Remedies trades at a PE of 58.77 and a PB of 5.56. On return on equity, the three post 4.85%, 18.42% and 10.90% respectively, and on dividend yield they stand at 1.18%, 0.42% and 0.00%. Syncom Formulations (India) has the highest market capitalisation of the three at Rs 2,217 crore, while Shree Ganesh Remedies has the lowest at Rs 907 crore. Shree Ganesh Remedies has the highest PE ratio of the three at 58.77, while Syncom Formulations (India) has the lowest at 25.91. Syncom Formulations (India) has the highest return on equity of the three at 18.42%, while Kopran has the lowest at 4.85%. Kopran has the highest debt to equity ratio of the three at 0.29, while Syncom Formulations (India) has the lowest at 0.00. Debt to equity is 0.29, 0.00 and 0.19 for the three respectively.
Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) | YoY Change (Net Profit) |
|---|---|---|---|---|---|
| Kopran | Rs 156.04 crore | Rs 6.70 crore | +13.3% | -33.3% | -10.1% |
| Syncom Formulations (India) | Rs 133.36 crore | Rs 24.85 crore | +8.5% | -11.1% | +57.8% |
| Shree Ganesh Remedies | Rs 15.30 crore | Rs 1.12 crore | -39.6% | -55.3% | -67.5% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.
Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies: Five-Quarter Revenue and Net Profit Trend
The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies, which helps separate a one-quarter move from a steadier pattern.
Quarterly revenue (Rs crore)
| Quarter | Kopran | Syncom Formulations (India) | Shree Ganesh Remedies |
|---|---|---|---|
| June 2025 | Rs 137.78 crore | Rs 122.93 crore | Rs 25.33 crore |
| September 2025 | Rs 117.94 crore | Rs 126.97 crore | Rs 31.01 crore |
| December 2025 | Rs 194.35 crore | Rs 120.64 crore | Rs 21.77 crore |
| March 2026 | Rs 234.11 crore | Rs 149.96 crore | Rs 34.22 crore |
| June 2026 | Rs 156.04 crore | Rs 133.36 crore | Rs 15.30 crore |
Quarterly net profit (Rs crore)
| Quarter | Kopran | Syncom Formulations (India) | Shree Ganesh Remedies |
|---|---|---|---|
| June 2025 | Rs 7.45 crore | Rs 15.75 crore | Rs 3.45 crore |
| September 2025 | -Rs 9.92 crore | Rs 16.60 crore | Rs 4.96 crore |
| December 2025 | Rs 9.34 crore | Rs 18.91 crore | Rs 3.09 crore |
| March 2026 | Rs 18.87 crore | Rs 25.17 crore | Rs 6.27 crore |
| June 2026 | Rs 6.70 crore | Rs 24.85 crore | Rs 1.12 crore |
Kopran reported revenue of Rs 137.78 crore in June 2025 and Rs 156.04 crore in June 2026, a change of +13.3% across the period. Its highest quarterly revenue in this window was Rs 234.11 crore in March 2026. Net profit stood at Rs 6.70 crore in June 2026, which is a net profit margin of 4.29%. Kopran reported a net loss in September 2025.
Syncom Formulations (India) reported revenue of Rs 122.93 crore in June 2025 and Rs 133.36 crore in June 2026, a change of +8.5% across the period. Its highest quarterly revenue in this window was Rs 149.96 crore in March 2026. Net profit stood at Rs 24.85 crore in June 2026, which is a net profit margin of 18.63%.
Shree Ganesh Remedies reported revenue of Rs 25.33 crore in June 2025 and Rs 15.30 crore in June 2026, a change of -39.6% across the period. Its highest quarterly revenue in this window was Rs 34.22 crore in March 2026. Net profit stood at Rs 1.12 crore in June 2026, which is a net profit margin of 7.32%.
Download the Univest iOS App or Univest Android App to track Kopran, Syncom Formulations (India) and Shree Ganesh Remedies live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and biotech names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, raw material costs and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.
It also helps to read the latest quarterly filings and investor presentations of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.
Conclusion
Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies highlights how differently three companies in the same pharma and biotech segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Kopran vs Syncom Formulations (India) vs Shree Ganesh Remedies
What is the market cap difference between Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?
Ans. As of October 2026, Kopran has a market cap of approximately Rs 1,227 crore, Syncom Formulations (India) is at approximately Rs 2,217 crore, and Shree Ganesh Remedies is at approximately Rs 907 crore.
What are the PE and PB ratios of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?
Ans. As of October 2026, the PE ratios stand at 49.10, 25.91 and 58.77 respectively, and the price to book ratios stand at 2.31, 5.34 and 5.56 respectively.
Which of the three has the highest ROE?
Ans. Kopran, Syncom Formulations (India) and Shree Ganesh Remedies post ROE of 4.85%, 18.42% and 10.90% respectively as of October 2026. Syncom Formulations (India) has the highest return on equity of the three at 18.42%, while Kopran has the lowest at 4.85%.
Which of these three stocks pays the highest dividend yield?
Ans. Kopran, Syncom Formulations (India) and Shree Ganesh Remedies carry dividend yields of 1.18%, 0.42% and 0.00% respectively.
What is the debt to equity ratio for Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?
Ans. Kopran carries a debt to equity of 0.29, Syncom Formulations (India) of 0.00, and Shree Ganesh Remedies of 0.19.
What were the latest quarterly revenue and net profit of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?
Ans. For Q1 FY27 (quarter ended June 2026), Kopran reported revenue of Rs 156.04 crore and net profit of Rs 6.70 crore, Syncom Formulations (India) reported revenue of Rs 133.36 crore and net profit of Rs 24.85 crore, and Shree Ganesh Remedies reported revenue of Rs 15.30 crore and net profit of Rs 1.12 crore.
Does this comparison recommend one of Kopran, Syncom Formulations (India) and Shree Ganesh Remedies?
Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.